<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527185</url>
  </required_header>
  <id_info>
    <org_study_id>2000028772</org_study_id>
    <secondary_id>1R03AA028361-01A1</secondary_id>
    <nct_id>NCT04527185</nct_id>
  </id_info>
  <brief_title>Effect of Endotoxin on Alcohol Consumption</brief_title>
  <official_title>Does Endotoxin Administration Increase Alcohol Consumption in Individuals With AUD?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For this protocol, the investigators plan to collect pilot data to examine the effect of&#xD;
      endotoxin on drinking behavior in the human laboratory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study is a double-blind, placebo-controlled design, which will compare endotoxin&#xD;
      (0.4ng/kg i.v.) to placebo (0.0ng/kg) in non-treatment seeking adults meeting criteria for&#xD;
      DSM-5 alcohol use disorders (n=32 total, n=16 per group).&#xD;
&#xD;
      Eligibility screening consists of an intake session and a physical exam. Participants meeting&#xD;
      eligibility criteria will be randomized to receive a single dose of 0.4ng/kg i.v. endotoxin&#xD;
      or placebo during a single laboratory session to evaluate ad-libitum alcohol consumption.&#xD;
&#xD;
      During the laboratory session, endotoxin (or placebo) administration will precede a 2-hour&#xD;
      alcohol self-administration period.&#xD;
&#xD;
      Participants will be scheduled for a follow-up appointment to evaluate drinking behavior.&#xD;
&#xD;
      Adverse events are evaluated during the laboratory session and follow-up, and will be&#xD;
      tabulated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol consumption</measure>
    <time_frame>120 minutes</time_frame>
    <description>Mean mls of alcohol consumed for endotoxin and placebo groups during 120 minute alcohol self-administration session.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Endotoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered one time during the laboratory session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>Endotoxin 0.4ng/kg i.v.</description>
    <arm_group_label>Endotoxin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lipopolysaccharide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 21-65;&#xD;
&#xD;
          2. Able to read and write English;&#xD;
&#xD;
          3. Meets DSM-5 criteria for current (past 6 months) alcohol use disorder;&#xD;
&#xD;
          4. Drinking criteria: Males - Drinks &gt; 14 drinks per week and exceeds 4 drinks per day at&#xD;
             least twice per week; Females -Drinks &gt; 7 drinks per week and exceeds 3 drinks per day&#xD;
             at least twice per week.&#xD;
&#xD;
          5. Must meet drinking criteria during a consecutive 30-day period within the 90 days&#xD;
             prior to baseline;&#xD;
&#xD;
          6. Laboratory sessions will be scheduled such that subjects will not have major&#xD;
             responsibilities on the following day which might limit drinking during the&#xD;
             self-administration session (e.g., job interview, exam).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with any significant current medical conditions (neurological,&#xD;
             cardiovascular [including hypertension or hypotension: sitting BP &gt;160/100 or&#xD;
             &lt;90/60mmHg at baseline screening], endocrine, thyroid, renal, liver), seizures,&#xD;
             delirium or hallucinations, or other unstable medical conditions including HIV;&#xD;
&#xD;
          2. Current DSM-5 substance use disorders, other than alcohol or nicotine;&#xD;
&#xD;
          3. A positive test result at intake appointment on urine drug screens conducted for&#xD;
             illicit drugs, excluding cannabis;&#xD;
&#xD;
          4. Past 30 day use of psychoactive drugs including anxiolytics and antidepressants;&#xD;
&#xD;
          5. Women who are pregnant or nursing, or fail to use one of the following methods of&#xD;
             birth control unless she or partner is surgically sterile or she is postmenopausal&#xD;
             (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive&#xD;
             sponge, double barrier [diaphragm or condom plus spermicide], or IUD);&#xD;
&#xD;
          6. Suicidal, homicidal or evidence of current (past 6-month) severe mental illness such&#xD;
             as schizophrenia, bipolar disorder or major depression, or anxiety disorders;&#xD;
&#xD;
          7. Subjects treatment-seeking or who are currently in treatment for alcohol use;&#xD;
&#xD;
          8. Subjects with medical conditions contraindicating alcohol use (e.g., liver enzymes ≥3×&#xD;
             normal);&#xD;
&#xD;
          9. Subjects likely to exhibit clinically significant alcohol withdrawal during the study.&#xD;
             We will exclude subjects who a) have a history of perceptual distortions, seizures,&#xD;
             delirium, or hallucinations upon withdrawal, or b) have a score of &gt; 8 on the Clinical&#xD;
             Institute Withdrawal Assessment scale at intake appointments;&#xD;
&#xD;
         10. Participation within the past 8 weeks in other studies that involve additive blood&#xD;
             sampling and/or interventional measures that would be considered excessive in&#xD;
             combination with the current application.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terril Verplaetse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terril Verplaetse, PhD</last_name>
    <phone>203-737-6496</phone>
    <email>terril.verplaetse@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meaghan Lavery</last_name>
    <phone>203-737-2783</phone>
    <email>meaghan.lavery@yale.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Terril Verplaetse</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

